RLA-5331

• Description :

  RLA-5331 is an iron activator containing anti-androgen. RLA-5331 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line[1].

• UNSPSC :

  12352005

• Target :

  Androgen Receptor

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/rla-5331.html

• Solubility :

  10 mM in DMSO

• Smiles :

  N#CC1=C(C=C(C=N1)N2C(C3(N(C2=S)C4=CC=C(N=C4)OC5CCN(CC5)C(O[C@@H]6CCC[C@@]7(OOC8(C9CC%10CC(CC8C%10)C9)O7)C6)=O)CCC3)=O)C(F)(F)F

• Molecular Formula :

  C40H43F3N6O7S

• Molecular Weight :

  808.87

• References & Citations :

  [1]Gonciarz RL, et al. Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. Eur J Med Chem. 2023 Jan 14;249:115110.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported